ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SQZ SQZ Biotechnologies Company

0.435
0.00 (0.00%)
Pre Market
Last Updated: 20:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price
Ask Price
News -
Day High

Low
0.25

52 Week Range

High
0.568

Day Low
Company Name Stock Ticker Symbol Market Type
SQZ Biotechnologies Company SQZ NYSE Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.435 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.435
Trades Volume Avg Volume 52 Week Range
0 0 - 0.25 - 0.568
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.435 USD

SQZ Biotechnologies Company Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
12.68M 29.49M - 21.48M -79.46M -2.69 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

SQZ Biotechnologies News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SQZ Message Board. Create One! See More Posts on SQZ Message Board See More Message Board Posts

Historical SQZ Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.5680.5680.250.4294973,187,004-0.133-23.42%
3 Years13.6016.170.253.44234,217-13.17-96.80%
5 Years14.0036.490.256.05219,023-13.57-96.89%

SQZ Biotechnologies Description

SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.

Your Recent History

Delayed Upgrade Clock